Within PC3 cells the co-treatment of cancer cells with TRAIL at the concentration of 100 ng/mL and paclitaxel at the concentrations of 0.25 μM and 0.5 μM increased the percentage of apoptotic cells, respectively, to 30.2% ± 5.7% and 34.2% ± 4.1% in CSCs subpopulation, and to 72.6% ± 7.1% and 75.9% ± 7.3% in non-CSCs subpopulation. The gene discussed is TNFSF10; the disease is cancer.